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AKT/mTOR pathway activation and BCL-2 family proteins
modulate the sensitivity of human small cell lung cancer cells to
RAD001
Abstract
PURPOSE: The Akt/mammalian target of rapamycin (mTOR) pathway is frequently activated in human
cancers and plays an important role in small cell lung cancer (SCLC) biology. We investigated the
potential of targeting mTOR signaling as a novel antitumor approach in SCLC. EXPERIMENTAL
DESIGN: The expression of mTOR in patient specimens and in a panel of SCLC cell lines was
analyzed. The effects on SCLC cell survival and downstream signaling were determined following
mTOR inhibition by the rapamycin derivative RAD001 (Everolimus) or down-regulation by small
interfering RNA. RESULTS: We found elevated expression of mTOR in patient specimens and SCLC
cell lines, compared with normal lung tissue and normal lung epithelial cells. RAD001 treatment
impaired basal and growth factor-stimulated cell growth in a panel of SCLC cell lines. Cells with
increased Akt pathway activation were more sensitive to RAD001. Accordingly, a constitutive
activation of the Akt/mTOR pathway was sufficient to sensitize resistant SCLC cells to the cytotoxic
effect of RAD001. In the sensitive cells, RAD001 showed a strong additive effect to the proapoptotic
action of the chemotherapeutic agent etoposide. Intriguingly, we observed low Bcl-2 family proteins
levels in the SCLC cells with a constitutive Akt pathway activation, whereas an increased expression
was detected in the RAD001-resistant SCLC cells. An antisense construct targeting Bcl-2 or a
Bcl-2-specific inhibitor was able to sensitize resistant SCLC cells to RAD001. Moreover, SCLC tumor
growth in vivo was significantly inhibited by RAD001. CONCLUSION: Together, our data show that
inhibiting mTOR signaling with RAD001 potently disrupts growth and survival signaling in human
SCLC cells.
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Statement of Translational Relevance: 
 
Small cell lung cancer (SCLC) is a devastating disease. The present report highlights the 
importance of mTOR and Bcl-2 family proteins for the chemoresistance of SCLC. Based on our 
data, targeting mTOR by the commercially available and clinically approved inhibitor RAD001 
(Everolimus) significantly reduces SCLC cell growth and proliferation. Moreover, RAD001 
further sensitizes SCLC cells to  the anti-tumor effects of commonly used chemotherapeutic 
drugs. Importantly, the differences in SCLC cells responsiveness to the RAD001 are based on 
the activation status of the Akt/mTOR pathway and the expression levels of Bcl-2 family 
proteins. Based on our findings, for a clinical relevant application it may be of advantage to 
screen SCLC patients for Akt/mTOR pathway activation status and Bcl-2 family expression prior 
to considering the use of RAD001 in combination with chemotherapeutic agents such as 
etoposide. 
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Abstract 
Purpose: The Akt/mTOR pathway is frequently activated in human cancers and plays an 
important role in small cell lung cancer (SCLC) biology. We investigated the potential of 
targeting mTOR signaling as a novel anti-tumor approach in SCLC.  
Experimental design: The expression of mTOR in patient specimens and in a panel of SCLC 
cell lines was analyzed. Effects on SCLC cells survival and downstream signaling were 
determined following mTOR inhibition by the rapamycin derivative RAD001 (Everolimus) or 
down-regulation by siRNA.    
Results: We found elevated expression of mTOR in patient specimens and SCLC cell lines, 
compared to normal lung tissue and normal lung epithelial cells. RAD001 treatment impaired 
basal and growth factor-stimulated cell growth in a panel of SCLC cell lines. Cells with 
increased Akt pathway activation were more sensitive to RAD001. Accordingly, a constitutive 
activation of the Akt/mTOR pathway was sufficient to sensitize resistant SCLC cells to the 
cytotoxic effect of RAD001. In the sensitive cells, RAD001 showed a strong additive effect to the 
pro-apoptotic action of the chemotherapeutic agent etoposide. Intriguingly, we observed low 
Bcl-2 family proteins levels in the SCLC cells with a constitutive Akt pathway activation, whereas 
an increased expression was detected in the RAD001-resistant SCLC cells. An antisense 
construct targeting Bcl-2 or a Bcl-2 specific inhibitor were both able to sensitize resistant SCLC 
cells to RAD001. Moreover, SCLC tumor growth in vivo was significantly inhibited by RAD001.  
Conclusion: Together, our data demonstrate that inhibiting mTOR signaling with RAD001 
potently disrupts growth and survival signaling in human SCLC cells.  
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Introduction 
Lung cancer is a major cause of death in the developed world. Small-cell lung cancer (SCLC) 
represents ~20% of all cases of lung cancer and is strongly correlated with cigarette smoking. 
Etoposide-based chemotherapy and radiotherapy treatment are commonly used. However, an 
initial therapeutic responsiveness is followed by disease recurrence and the overall five year 
survival rate is less than 5%. Consequently, novel therapeutic strategies are urgently required. 
In recent years, a rising number of biological dysfunctions involved in SCLC pathogenesis were 
reported, including ectopic expression of neuro-endocrine regulatory peptides, over- expression 
of Myc family oncogenes and extracellular matrix proteins, as well genetic abnormalities in the 
tumor suppressor genes p53 and pRB (1, 2). Moreover, it has been shown that polypeptide 
growth factors such as stem cell factor (SCF) and fibroblast growth factor-2 (FGF-2) induce a 
variety of responses in human SCLC cells, including growth and proliferation, chemoresistance 
and motility (3-6). Activation of two major intracellular signaling cascades, the phosphoinositide-
3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and the mitogen-activated Erk 
kinase (MEK)/extracellular signal-regulated kinase (Erk) pathway, have been found to be 
involved in the survival and proliferation of SCLC (3, 5-8). Furthermore, it has been found that 
the ribosomal protein S6 kinases-1 and -2 (S6K1, 2) are highly over-expressed in SCLC cells 
compared to normal human type II pneumocytes, and that mTOR transduces mitogen-induced 
proliferation in SCLC (6). Therefore targeting these pathways with novel anti-cancer agents may 
pave the way for more effective therapy of SCLC.  
It has been shown that mTOR is a highly conserved, ubiquitously expressed signaling 
molecule, which is activated downstream of multiple distinct growth factor receptors and is of a 
crucial importance for mediating cell proliferation and survival. These mTOR-dependent cell 
processes can be blocked by rapamycin and its derivatives RAD001 and CCI-779, and thus a 
new cancer-related therapy was proposed (9). Rapamycin was discovered as a fungicide 
produced by Streptomyces hygroscopicus and its antitumor activity was documented in many 
studies, but stability and solubility problems required the synthesis of derivatives such as 
RAD001 and CCI-779 with improved properties (9, 10). 
mTOR is a 289 kDa serine/threonine kinase which belongs to the PI3K-related protein 
kinase family. Activation of mTOR leads to activation of S6K1 and phosphorylation of the 
ribosomal S6 protein and of the eukaryotic translation initiation factor 4E (eIF4E)-binding protein 
1 (4E-BP1), resulting in both ribosome biogenesis and cap-dependent mRNA translation. Thus 
activation of mTOR is required for G1 cell-cycle progression and S-phase initiation. Inhibition of 
mTOR with rapamycin induces a G1 cell-cycle arrest. Furthermore, it was recently reported that 
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rapamycin and its derivative RAD001 disrupt the cyclin D1/Cdk2/p21WAF1 complex in tumor cells, 
which leads to cell cycle arrest (11). RAD001 also dramatically enhances cisplatin-induced 
apoptosis in tumor cells expressing wild type p53, by inhibiting p53-induced p21WAF1 expression 
(12). Findings by other group have suggested that rapamycin induces apoptosis in tumor cells 
by down-regulation of Bcl-XL and up-regulation of Bax, while there was no significant effect on 
the cell cycle (13). 
However, it was recently shown that rapamycin derivatives inhibit an mTOR-dependent 
serine phosphorylation of the insulin receptor substrate-1 (IRS-1), and thus enhance insulin-like 
growth factor-I (IGF-I) signaling and downstream PI3K/Akt activation. (14). This response was 
abrogated by pre-treatment of the cells with a specific insulin-like growth factor-I receptor (IGF-
IR) inhibitor (15). Thus, induction of Akt activity by mTOR inhibition leads to resistance to 
pharmacological mTOR inhibitors, but blocking the IGF-IR reverses the Akt activation and the 
cell’s resistance. 
Here we report that RAD001 blocks SCLC cell growth in vitro and in vivo and present 
evidence that the Akt/mTOR pathway activation status, as well as Bcl-2 family proteins 
expression modulate the cell’s sensitivity to the drug.  
 
Materials and Methods 
Reagents and antibodies 
Antibodies against Akt1, caspase-3, Erk1/2, ICAD, MDM2, H-Ras, p21WAF1 and PARP were 
obtained from Santa Cruz Biotechnology. Antibodies against activated Akt (Ser473), Bcl-2, Bcl-
XL, Bax, Thr37/46-phosphorylated-4E-BP, Ser235/236- or Ser240/244-phosphorylated-protein 
S6, total S6 protein were from Cell Signalling Technology. Antibodies against β-actin, β-tubulin 
and activated Erk1/2 (Thr202/Tyr204) were from Sigma Aldrich. Etoposide, z-VAD-FMK, SCF, 
FGF-2, bombesin and vasopressin were from Calbiochem. 3-methyladenine was from Sigma-
Aldrich. RAD001 was supplied by the Novartis Institutes for BioMedical Research Basel, 
Oncology, Switzerland. The Bcl-2 Inhibitor III, EM20-25, was obtained from Calbiochem. 
 
 
 
 
Tissue samples 
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Normal lung tissue and SCLC tissue microarray were obtained from US Biomax, Inc. (Rockville, 
USA), code BN04011 (http://www.biomax.us/tissue-arrays/Lung/BN04011) and BS04111 
(http://www.biomax.us/tissue-arrays/Lung/BS04111) respectively.   
 
Cell lines, cell culture, cell proliferation and apoptosis 
Human SCLC lines were cultured as described (5). For experimental purposes the SCLC cells 
were diluted into serum-free medium (SFM) and grown for 3-5 days. Human Type II 
pneumocytes were isolated and cultivated as described (6). 
SCLC cells (2 x 105/ml) were grown for 3 days in serum-containing medium in the presence or 
absence of RAD001. Cell proliferation was analyzed by MTS assay using the CellTiter 96® 
Aqueous One Solution Cell Proliferation Assay (Promega). Alternatively, cell counting 
experiments based on Trypan Blue exclusion were performed. SCLC cells grown in RPMI 
containing 10% FCS, were washed four times in RPMI and resuspended in SFM. Cells were 
then aliquoted in 24-well Falcon plates at a density of 1.5 x 104 cells/ml in the presence or 
absence of inhibitors and/or growth factors. After the relevant incubation period, cell clumps 
within the cell suspension were disaggregated by passing the well content 5 times through a 19-
gauge needle and the number of viable cells determined by Trypan Blue exclusion, using a 
haemocytometer. Each condition was performed in quadruplicate and results obtained from 
averaging the values of three counts per replicate.  
For detection of apoptosis, SCLC cells (2 x 106/ml) were incubated for 24 h in the presence or 
absence of RAD001 and/or etoposide. The cells were then lysed and samples analyzed by 
SDS-PAGE and Western blot with anti-poly (ADP-ribose) polymerase (PARP), anti-caspase-3, 
or anti-ICAD antibodies. Additionaly, apoptosis was analysed by caspase 3/7 activation using 
the Caspase-Glo 3/7 Assay (Promega), according to manufacturer’s instruction.    
 
 
In vivo experiments 
The effects of RAD001 on growth of established H-69 tumours in vivo were assessed in adult 
ICRF nude mice (Cancer Research-UK BSU, Clare Hall, South Mimms, UK). The xenograft was 
established by injecting 107 H-69 SCLC cells in 0.2 ml PBS subcutaneoulsy into one flank and 
subsequently passaged as previously described (16). RAD001 (5 mg/kg) or placebo were 
administered daily by oral gavage (5 animals per group). Tumour growth was monitored over a 
4-week period. 
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SDS-PAGE and Western blotting 
These assays were performed exactly as described (3). 
 
RT-PCR and TaqMan Analysis 
Total cellular RNA was extracted using the RNeasy Mini Kit (QIAGEN) according to the 
manufacturer’s instruction. For each RT-PCR, 1 μg of total RNA was used with the QIAGEN 
One-Step RT-PCR Kit. The following primers were used: mTOR, sense 5`- CTG GGA CTC AAA 
TGT GTG CAG TTC- 3`, and antisense, 5`- GAA CAA TAG GGT GAA TGA TCC GGG- 3`, 
Glyceraldehyde-3-phosphate dehydrogenase primer, sense, 5`- GAA GGT GAA GGT CGG 
AGT C-3`, and antisense, 5`- GAA GAT GGT GAT GGG ATT TC-3`. The reaction condition 
were as follows: reverse transcription at 50°C for 30 min, initial PCR activation at 95°C for 
15 min followed by 30 cycles at 95°C for 30 s, 54°C for 60 s and 72°C for 45 s. The PCR 
products were analysed in 1% agarose gel. TaqMan Gene Expression Assay for Bcl-2 was 
performed according to the manufacturer’s protocol. 
 
Immunohistochemistry 
mTOR immunoreactivity was evaluated on TMA sections using a mTOR monoclonal antibody 
(Cell Signaling, mTOR (7C10) #2983)  in a modification of the antigen retrieval technique of Shi 
and colleagues (17). Briefly, the sections were rehydrated in graded alcohols, heated in a 
microwave oven at 900W for 20 min in Citrate Buffer at pH 6. They were cooled at room 
temperature before the immunostains. mTOR MoAb was used at 1:20 dilution for 1 hours at 
room temperature and then processed with Polymer-HRP Kit (BioGenex, San Ramon CA)  with 
Diaminobenzidine development and Mayer haematoxylin counterstaining. An mTOR positive 
cell line cytoblock was used as positive external control. Negative controls were obtained by 
omitting the primary antibody. 
 
 
 
Immunohistochemistry scoring 
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A semiquantitative immunohistochemical score (IHS) was used including assessment of both 
the intensity of staining and the percentage of positive cells. In addition for the intensity, a score 
of 0 to 3, corresponding to negative, weak, moderate and strong positivity, was recorded. The 
range of possible scores was thus 0 to 300.  IHS and similar semiquantitative scoring systems 
have been successfully used for TMA evaluation (18-20). Each core was scored individually. If 
more than one core was evaluated from each tumor the mean score was calculated. If one core 
was uninformative the score applied was the mean of the remaining cores. One observer scored 
all cases, which were rechecked randomly by the same investigator after a period of time. A 
good correlation was found between the two estimations. 
 
Transient transfection of SCLC cells 
H-69 or H-510 cells were transfected with either non targeting siRNA or SMARTpool siRNA 
duplexes targeting mTOR (Dharmacon), using the Amaxa Nucleofector system (Amaxa 
biosystems), according to the manufacturer’s protocol. The same protocol was used to transfect 
H-510 cells with the anti-sense oligonucleotide 4625 targeting Bcl-2 or a corresponding 
scrambled sequence control (21). Briefly, 1.5 x 106 SCLC cells grown in RPMI/10% FCS were 
transfected with 6µl of 20µM siRNA in 100 µl of Nucleofector Solution V using the program T-16 
on the Amaxa Nucleofector. Following transfection, cells were transferred into RPMI/10% FCS 
overnight before they were used for experiments. 
 
Statistical analysis 
Analysis of variance and Bonferroni multiple comparison test or Kruskal-Wallis non-parametric 
analysis of variance test were used to assess statistical significance of differences between 
groups. The non-parametric Mann-Whitney test was used to compare the medians of two 
unpaired groups. P values <0.05 were considered as significant. 
 
 
 
 
Results 
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mTOR and downstream targets are up-regulated in human SCLC cell lines and patient 
specimens 
The protein expression levels and the activation status of signaling molecules involved in the 
mTOR pathway were compared between purified Type II lung epithelial cells and a panel of 
seven human SCLC cell lines. Our analysis revealed that mTOR and S6K1 were consistently 
expressed in the lung tumor cell lines (Figure 1a). Moreover, the protein levels of mTOR, S6K1 
and the phosphorylation of 4E-BP1 were elevated in SCLC cell lines, as compared to Type II 
epithelial cells (Figure 1a). Elevated levels of phosphorylated Akt were also found in some of the 
SCLC cell lines. In contrast, there was no increase in the levels of activated or total Erk1/2, or in 
the phosphorylation of the ribosomal S6 protein on Ser235/236 or Ser240/244 (Figure 1a).  
We further investigated the mTOR expression by immunohistochemistry in a total of 30 normal 
lung tissues samples and 30 SCLC patients samples (Figure 1b). We found that 50% of the 
SCLC specimens were positive for mTOR, whereas mTOR expression was not detectable in 
normal lung tissue (Figure 1c). Together, these data indicate that up-regulation of signaling 
enzymes involved in the mTOR pathway may contribute to the abnormal growth and survival 
properties of human SCLC cells. 
 
RAD001 inhibits SCLC cell growth in vitro 
To investigate the contribution of mTOR signaling to SCLC cell growth, the impact of the 
rapamycin derivative RAD001 (Everolimus) on the growth of HC-33, H-69, H-209, H-510, H524, 
H1622 and H2171 SCLC cell lines, and immortalized Type II pneumocytes was studied. On the 
basis of RAD001 sensitivity we observed two groups of SCLC cell lines. H-209, H-510 and H-
2171 cells showed high resistance to RAD001 (Figure 2a left), whereas the growth of HC-33, H-
69, H-524 and H-1622 cells was inhibited at sub-micromolar concentrations of RAD001 in a 
serum-containing medium (Figure 2a right). Intriguingly, the relative sensitivity of H-69, H-524 
and H-1622 cells to RAD001 treatment correlated with the enhanced phosphorylation of Akt 
and/or 4E-BP1 in these cell lines, as compared to H-209, H-510 and H-2171 cells (Figure 1a). 
Type II pneumocytes were also relatively resistant to RAD001 (Figure 2a), with 40% inhibition of 
cell growth observed only at 10 μM (data not shown). In addition, RAD001 inhibited basal H-69 
cell growth in serum-free medium (data not shown). The inhibitory effect of RAD001 was also 
observed when SCLC cell growth in liquid culture was investigated in response to bombesin, 
FGF-2, SCF, or vasopressin (Figure 2b-c and Supplemental Figure 1 a-b). In H-69 and H-510 
cells, low doses of rapamycin or RAD001 completely blocked growth induced by polypeptide 
(FGF-2, SCF), or neuropeptide (bombesin, vasopressin) growth factors in liquid culture (Figure 
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2b-c and Supplemental Figure 1 a-b). Together these data demonstrate that the mTOR pathway 
is critical for basal and growth factor-stimulated proliferation in SCLC cells. 
 
RAD001 impairs basal and SCF-stimulated activation of the mTOR pathway  
To further elucidate the molecular mechanism of SCLC cells proliferation inhibition by RAD001, 
the impact of the drug on basal mTOR activation and early signaling events stimulated by SCF 
was investigated. The basal phosphorylation of the S6 protein in Type II pneumocytes, H-69, H-
1622 and H-510 cells was completely blocked after treatment with 1 nM RAD001 after 20 hours 
in serum-containing medium (Supplemental Figure 1c). Pre-treatment of H-69 and H-510 cells 
with increasing concentrations of RAD001 completely abrogated SCF-stimulated 
phosphorylation of the S6 protein (Supplemental Figure 1d-e). In contrast, the drug did not 
markedly impair activation of Erk1/2 by SCF (Supplemental Figure 1e). A partial inhibition of 
SCF-stimulated Akt phosphorylation on Ser473 was observed upon RAD001 treatment 
(Supplemental Figure 1d), while a weak induction of Akt activation was observed in resting  H-
69 cells pre-treated with RAD001 at high doses (Supplemental Figure 1d). Similar results were 
obtained when S6K activation by other polypeptide growth factors was studied in SCLC cells. 
RAD001 inhibited phosphorylation of the ribosomal S6 protein by HGF and FGF-2 in the two cell 
lines under study (data not shown). The effect of RAD001 on basal and SCF-stimulated 
phosphorylation of the S6 protein in H-69 and H-510 cells was dose-dependent, with a maximal 
effect at 1 nM and was apparent after 1 h of pre-treatment (Supplemental Figure 1d-e). 
Together these results show that RAD001 selectively blocks the mTOR signaling pathway, 
which was previously implicated in SCLC cell growth, but not other pathways such as MEK/Erk 
(6).  
 
RAD001 impairs SCLC tumor growth in vivo 
To investigate the potential ability of RAD001 to inhibit SCLC tumor growth in vivo, a xenograft 
of H-69 SCLC cells was established by subcutaneous injection in nu/nu mice. The mice were 
then given placebo or RAD001 (5 mg/kg) daily by oral gavage over a 4-week period. The 
xenografts of placebo-treated animals displayed a 4-fold increase in tumor volume after 4 
weeks, while no increase was observed in mice treated with RAD001 (Figure 2d). Moreover, 
RAD001 induced a sustained decrease in tumor volume between 3-4 weeks of treatment 
(Figure 2d). 
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RAD001 sensitizes human SCLC cells to etoposide 
In view of the ability of RAD001 to block SCLC cell proliferation, we next investigated whether 
the drug could enhance the effect of the chemotherapeutic agent etoposide in these cells. H-69, 
H-510 and Type II pneumocytes were treated with three different concentrations of etoposide 
(0.3-3.0 μM) alone or in the presence of 1 nM RAD001. In the H-69 cell line, RAD001 treatment 
markedly enhanced the cytotoxic effects of etoposide (Figure 3a). However, a comparable effect 
was not observed in H-510 cells and Type II pneumocytes, which are less sensitive to RAD001 
(Figure 3a).  
In view of the ability of RAD001 to sensitize SCLC cells to etoposide, we then 
investigated whether the drug contributes to an increase in apoptosis in H-69 cells. The 
induction of apoptosis was assessed by Western blot analysis to detect the cleaved fragments 
of caspase-3, poly (ADP-ribose) polymerase (PARP) and inhibitor of caspase-activated DNase 
(ICAD). RAD001 as a single agent induced apoptosis at high concentration (100 nM) in H-69 
cells, as evidenced by Caspase-3, PARP and ICAD cleavage (Figure 3b).  H-69 cells treated 
with different etoposide doses displayed a marked induction of caspase-3, PARP and ICAD 
cleavage with increasing concentrations of RAD001, demonstrating enhanced induction of 
apoptosis upon combination treatment (Figure 3b). A comparable effect was not observed in H-
510 cells and Type II pneumocytes (Supplemental Figure 2a). Interestingly, untreated H-69 cells 
displayed high levels of p21WAF1 and MDM2, and RAD001 treatment decreased markedly the 
levels of both proteins (Figure 3b). In contrast, RAD001 alone or in combination with etoposide 
did not alter the levels of Bcl-2, Bcl-XL or Bax (Figure 3b).  
RAD001 at high concentration (100 nM) and etoposide alone induced caspase-3 
cleavage into the active 17 kDa and 12 kDa subunits, and the combination treatment further 
strongly enhanced the appearance of the two bands (Figure 3c). Pre-treatment of the cells with 
20 μM z-VAD-FMK led to the disappearance of the 12 kDa band and to the accumulation of the 
pre-mature 20 kDa fragment (Figure 3c). Furthermore, pre-treating H-69 cells with 50 μM z-
VAD-FMK was sufficient to partially inhibit the effects of RAD001 alone, etoposide alone or of 
the combination treatment on cell viability (Figure 3d). Since an active mTOR pathway protects 
cells from autophagy and rapamycin treatment induces autophagy (22, 23), we tested whether 
the cytotoxic effect of RAD001 in SCLC cells is based on activated autophagy. H-69 cells were 
treated with 1mM 3-methyladenine, an inhibitor of autophagy, in the presence of RAD001 alone, 
etoposide alone or combination treatment (Figure 3d). 3-MA was able to rescue almost 
completely the cytotoxic effect of RAD001 alone and showed significant effect in the 
combination treatment with etoposide (Figure 3d), suggesting that induction of autophagy is a 
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major contributor to the reduction in cell viability observed in response to RAD001 treatment in 
SCLC cells.   
Together, these data demonstrate that blocking mTOR signaling with RAD001 induces 
autophagy and increases apoptosis induced by low doses of chemotherapeutic agents in 
human SCLC cells. 
 
SCLC cells with enhanced activation of the Akt/mTOR pathway are more sensitive to the 
effects of RAD001 
 
The results above indicated that the activation of the Akt/mTOR signaling in some SCLC cell 
lines may contribute to their enhanced sensitivity to RAD001. To further substantiate this 
hypothesis, we utilized H-510 cells transfected with a short hairpin RNA (shRNA) construct 
targeting H-Ras (H-510/H-Ras), which have a higher basal Akt activation compared to vector-
transfected H-510 cells (Figure 4a and Supplemental Figure 2b), as previously reported (24). 
Moreover, phosphorylation of both 4E-BP1 and the S6 protein was also enhanced in the 
H510/H-Ras cells (Figure 4a and Supplemental Figure 2b). Intriguingly, the H-510/H-Ras cells 
displayed markedly decreased levels of Bcl-2 protein, while Bcl-XL levels were only partially 
reduced (Figure 4a and Supplemental Figure 2b). We next investigated the mechanism of Bcl-2 
down-regulation in H-510/H-Ras cells. A quantitative gene expression analysis revealed a 
strong reduction in Bcl-2 mRNA levels in H-510/H-Ras cells, as compared to cells transfected 
with pRS-shGFP control vector (Figure 4b).  
RAD001 only moderately inhibited the proliferation of vector-transfected H-510 cells, 
although it did promote inhibition of S6 protein phosphorylation in these cells (Figure 4c and 
data not shown). In contrast to vector-transfected H-510 cells, the growth of H-510/H-Ras cells 
in liquid culture was strongly inhibited by RAD001 at sub-micromolar concentrations (Figure 4c 
and Supplemental Figure 2c), demonstrating that activation of the Akt/mTOR pathway is 
sufficient to sensitize H-510 cells to RAD001. 
 
Expression of anti-apoptotic Bcl-2 family members contributes to the resistance of SCLC 
cells to RAD001 
Rapamycin was previously reported to affect the levels of proteins of the Bcl-2 family in 
different tumor cells, which contributes to its growth-suppressive effects (13). In view of these 
findings, we sought to investigate the expression pattern of Bcl-2 proteins in SCLC cell lines and 
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its possible contribution to the sensitivity of the cells to RAD001. A comparative Western blot 
analysis revealed that the expression levels of the anti-apoptotic proteins Bcl-2 and Bcl-XL were 
elevated in SCLC cell lines, as compared to Type II pneumocytes (Figure 5a-b). Intriguingly, the 
H-209 and H-510 cell lines displayed higher levels of both Bcl-2 and Bcl-XL than the H-69 cell 
line, indicating a possible contribution to RAD001 resistance (Figure 5a-b and Figure 2a). To 
test the latter hypothesis, a specific anti-sense construct targeting Bcl-2 was tested in H-510 
SCLC cells. Effective down-regulation of the target protein Bcl-2 was confirmed by Western blot 
analysis (Figure 5c). H-510 cells transfected with specific Bcl-2 anti-sense displayed enhanced 
sensitivity to RAD001 (Figure 5d). Very recently, the small organic molecule EM20-25 has been 
reported to sensitize apoptosis-resistant cells to cytotoxic drugs by binding to Bcl-2 and 
disrupting its interaction with pro-apoptotic proteins, such as BAX and BAK (25, 26). A 
combination treatment of H-510 SCLC cells with 40 μM EM20-25, sensitized these cells to 
RAD001 in a dose-dependent manner (Figure 5e). The strong reduction of cell viability further 
correlated with an increase in Caspase-3/7 activity, which indicates induction of apoptosis 
(Figure 5f). Similar results were observed in H-209 SCLC cells (data not shown). Collectively, 
these data show that Bcl-2 family proteins levels modulate the sensitivity of SCLC cells to 
RAD001. 
 
RNA interference (RNAi) targeting mTOR selectively inhibits SCLC growth 
The results above revealed differences in sensitivities to RAD001 in a panel of SCLC 
cells lines. In order to confirm these results by an alternative approach, H-69 and H-510 SCLC 
cells were transiently transfected with small interfering RNA (siRNA) targeting mTOR. Western 
blot and RT-PCR analysis revealed down-regulation of mTOR, in both cell lines (Figure 6a-b). 
Transfection of H-69 and H-510 cells induced reduction in the phosphorylation of the mTOR 
downstream target 4E-BP1 (Figure 6a). Growth of the transfected H-69 cells was significantly 
affected by the mTOR siRNA, whereas no effect was observed in the H-510 cell line (Figure 6c). 
As shown in figure 6a, we did not observe a total mTOR pathway inhibition, as evidenced by 
residual phosphorylation of 4E-BP1, which may explain the partial inhibitory effect on H-69 cell 
growth. Together these data demonstrate that decreased levels of mTOR significantly affect 
proliferation in the H-69, but not in the H-510 cell line. 
  
Discussion 
In the present report, we have evaluated the potential of the rapamycin derivative 
RAD001 (Everolimus) as an anti-tumor agent in human SCLC cells. An immunohistochemistry 
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analysis revealed that mTOR is over-expressed in 50% of all tested SCLC patient tumor 
samples and we further found mTOR and S6K1 overexpression in a panel of SCLC cell lines, as 
compared to Type II pneumocytes. These findings correlated with enhanced phosphorylation of 
components of the Akt/mTOR pathway observed in the SCLC cell lines. Surprisingly, despite 
over-expression of mTOR and S6K1, enhanced phosphorylation of the ribosomal S6 protein 
was not observed in the SCLC cell lines, as compared to Type II pneumocytes. A possible 
explanation for these findings is that the constitutive activation of Erk1/2 observed in Type II 
pneumocytes is in part responsible for the phosphorylation of the S6 protein, which was also 
observed in mice with a targeted deletion of the S6K1 and S6K2 genes (27). Moreover, there 
was a lack of correlation between the phosphorylation levels of Akt and 4E-BP1 in the SCLC 
cell lines. 
In selected SCLC cell lines displaying enhanced phosphorylation/activation of 
components of the Akt/mTOR pathway (HC-33, H-69, H-524 and H-1622), RAD001 inhibited 
basal growth in vitro at sub-micromolar concentrations corresponding to those inducing 
suppression of S6 protein phosphorylation. Moreover, growth of the H-69 cell line as xenografts 
in nude mice was completely inhibited by oral administration of RAD001. Interestingly, RAD001 
treatment also induced tumor regression in H-69 xenografts. In other SCLC cell lines (H-209, H-
510 and H-2171), and immortalized Type II pneumocytes, cell proliferation was inhibited only at 
higher concentrations. This was supported by the findings that siRNA-mediated reduction of 
mTOR expression resulted in a significant effect on proliferation in the H-69, but not in the H-
510 cell line. These observations may be attributed to the fact that these SCLC cell lines require 
different thresholds of mTOR expression for proliferation. The differences in sensitivities 
between the SCLC cell lines were not caused by a defect in the mTOR pathway, since basal 
and growth factor-stimulated phosphorylation of the S6 protein were inhibited by RAD001 in H-
69 and H-510 cells with similar dose-dependencies. Moreover, in both cell lines, RAD001 
inhibited cell growth induced by polypeptide or neuropeptide growth factors. Although, as 
previously observed in other cell systems (14), RAD001 treatment of H-69 cells induced a weak 
activation of Akt, as assessed by the induction of Ser473 phosphorylation, other additional 
factors appeared to modulate the resistance of SCLC cells to RAD001. In addition, we observed 
a partial inhibition of SCF-induced activation of Akt upon RAD001 treatment of H-69 cells, which 
could be due to inhibition of the mTORC2 complex implicated in the regulation of Akt Ser473 
phosphorylation (28).  
Previous reports have documented increased sensitivity of PTEN-deficient cancer cells 
to rapamycin derivatives, implying that constitutive activation of the PI3K/Akt/mTOR pathway 
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renders tumor cells more sensitive to these drugs (29, 30). A similar observation was made here 
in SCLC cell lines, since cells with enhanced phosphorylation of components of the Akt/mTOR 
signaling pathway, were most sensitive to RAD001. Moreover, SCLC cells in which Akt/mTOR 
signaling was constitutively activated by transfection displayed enhanced sensitivity to RAD001. 
Surprisingly, Akt/mTOR pathway activation resulted in decreased levels of the anti-apoptotic 
protein Bcl-2 and, to a lesser extent, Bcl-XL. Accordingly, expression of Bcl-2 was high in 
RAD001-resistant SCLC cell lines (H-209, H-510 and H-2171), as compared to the sensitive cell 
lines (HC-33, H-69 and H524). Specific Bcl-2 antisense construct was able to restore RAD001 
sensitivity in resistant SCLC cells (H-510). Similar findings were recently reported in ovarian 
cancer cells, where the same anti-sense construct increased RAD001-mediated apoptosis (31). 
We could further confirm that the function of overexpressed Bcl-2 is sufficient to render SCLC 
cells resistant to RAD001. By co-treatment with RAD001 in the presence of a specific Bcl-2 
inhibitor (EM20-25) at concentrations previously reported to sensitize cancer cells to the pro-
apoptotic effects of chemotherapeutics (25), we observed strong reduction of cell viability in 
RAD001-resistant SCLC cell lines due to an increase in apoptosis. The simplest model 
accounting for these observations would be that RAD001-mediated apoptosis accounts in part 
for its growth-suppressing effects in SCLC cells. As a consequence, over-expression of anti-
apoptotic Bcl-2 family proteins would protect SCLC cells from RAD001-mediated cell death. The 
mechanism of Bcl-2 down-regulation in SCLC cell lines with enhanced Akt/mTOR signaling is 
unclear. Akt has previously been reported to phosphorylate and inactivate the pro-apoptotic Bcl-
2 family member Bad (32). It is conceivable that, in SCLC cells displaying enhanced Akt activity,  
high Bcl-2 expression levels are not required, since Bad is inactivated by Akt-mediated 
phosphorylation.  
Using a specific autophagy inhibitor we were able to rescue H-69 SCLC cells from the 
cytotoxic effect induced by RAD001 alone or in combination with etoposide, thus raising the 
possibility that RAD001 induces autophagy in the SCLC cells in addition to its effects on cell 
growth and apoptosis. Intriguingly, Bcl-2 has been reported to inhibit the autophagic response 
(33) and rapamycin also induced autophagy in malignant glioma cells (34). 
A recent report has described the mechanism of RAD001-mediated chemosensitization 
in NSCLC cells (A-549) through inhibition of p53-induced accumulation of p21WAF1 (12). The 
rapamycin derivative CCI-779 was also recently shown to sensitize SCLC cells to cisplatin-
induced apoptosis (35). Here we show that RAD001 can increase etoposide-induced apoptosis, 
independently of p53, since the H-69 cell line does not express p53 (36, 37). Interestingly, we 
observed high levels of p21WAF1 and MDM2 in untreated H-69 SCLC cells, and RAD001 
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treatment resulted in decreased levels of both proteins. Since p21WAF1 and MDM2 have been 
described as proteins with a short half-life (38, 39) and a recent study reported that reduced 
p21WAF1 protein expression in NSCLC cells (A-549) after RAD001 treatment was due to 
inhibition of global translation (12), we suppose that this could be a general mechanism 
facilitating the pro-apoptotic effect of RAD001. Recent studies further confirmed the anti-survival 
effect of rapamycin and its derivatives by decreasing p21WAF1 levels in different cancer types 
(40-42). Intriguingly, beside its established role as an apoptosis inhibitor (43), p21WAF1 has been 
recently reported to also block autophagy induction (44). Thus, inhibition of mTOR-dependent 
protein translation could affect the chemosensitivity of SCLC cells by decreasing the levels of 
p21WAF1 and MDM2. In contrast, Bcl-2, Bcl-XL or Bax levels were unaffected by RAD001 in 
SCLC cells. 
The rapamycin derivative CCI-779 was recently evaluated in a Phase II clinical trial in 
SCLC patients after induction chemotherapy (45). Although some beneficial effects were 
observed in the high dose group, some have argued that rapamycin derivatives may not be 
further considered for clinical trials in SCLC (45). The present report highlights significant 
differences in SCLC cells responsiveness to the rapamycin derivative RAD001. Based on our 
findings, it may be of advantage to screen SCLC patients for Akt/mTOR pathway activation 
status and/or Bcl-2 family expression prior to considering the use of RAD001 in combination 
with chemotherapeutic agents such as etoposide. 
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Figure legends 
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Fig. 1 Expression of mTOR and downstream signaling molecules in human SCLC cell lines and 
patient samples. (a) Equal amounts of lysates from purified human Type II lung epithelial cells 
(TII), or human SCLC cell lines (as indicated) were analyzed by SDS-PAGE and Western 
blotting with antibodies specific for the proteins indicated. (b) Immunostaining with mTOR 
showing negative SCLC staining and representative mTOR SCLC positive staining, compared 
to normal lung tissue. (c) The mean immunohistochemical staining scores (IHC scores) of 
mTOR in 30 paraffin-embedded specimens each of normal lung tissues and of 30 SCLC 
paraffin-embedded specimens. IHC scores = percentage of positive cells X staining intensity 
(for details, see “Materials and Methods”). 
 
   
Fig. 2 RAD001 blocks basal and growth factor-stimulated SCLC cell proliferation in vitro and 
inhibits H-69 tumor growth in vivo. (a) Type II pneumocytes, HC-33, H-69, H-209, H-510, H-524, 
H-1622 and H-2171 were incubated with increasing concentrations of RAD001 in serum-
containing medium. Cell proliferation was assessed using the MTS assay after 5 days. The data 
are mean with SD from 8 replicates and representative of at least three independent 
experiments. *, p<0.05. (b and c) H-69 (b) or H-510 (c) cells were incubated with vehicle (open 
bars), rapamycin (10 nM, black bars), or RAD001 (1 nM, grey bars) in serum-free medium in the 
presence or absence of FGF-2 (1.0 ng/ml) or SCF (10 ng/ml). Cell counting was performed at 
different days (where indicated). The data are mean with SD from 3 experiments. (d) Xenografts 
of H-69 SCLC cells were grown subcutaneously in adult nude mice. RAD001 (5 mg/kg, closed 
bars) or placebo (open bars) were administered by oral gavage daily and tumor growth 
monitored over a 4-week period. Tumor volume was determined at the times indicated. Data are 
mean from 5 animals in each group. *, p<0.05. 
 
 
Fig. 3 RAD001 sensitizes SCLC cells to the cytotoxic effect of etoposide. (a) H-69, H-510 and 
Type II pneumocytes grown in serum-containing medium were incubated with increasing 
concentrations of RAD001 alone (1 nM) or in combination with etoposide at concentrations 
indicated. Cell proliferation was assessed using the MTS assay after 5 days. The data are mean 
with SD from 3 experiments. (b) H-69 cells grown in serum-containing medium were incubated 
with increasing concentrations of RAD001 in the presence of etoposide at the concentrations 
indicated. After 24 hours, the cells were harvested and cell lysates analyzed by SDS-PAGE and 
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Western blot for the proteins indicated. (c) H-69 cells grown in serum-containing medium were 
pre-treated with 20 μM z-VAD-FMK 1h prior to incubation with RAD001 (100nM) alone, 
etoposide (10 μM) alone or combination treatment with both components. After 24 hours, the 
cells were harvested and cell lysates analyzed by SDS-PAGE and Western blot for the proteins 
indicated. (d) H-69 cells grown in serum-containing medium were incubated with RAD001 (100 
nM) alone, or in combination with etoposide (10 μM) in the presence or absence of zVAD (50 
μM) or 3-methyladenine (1mM). Cell proliferation was assessed using the MTS assay after 3 
days. The data are mean with SD from 3 independent experiments performed in quadruplicates. 
*, p<0.05. 
 
Fig. 4 Activation of Akt/mTOR signaling increases H-510 sensitivity to RAD001. (a) H-510 cells 
stably transfected with pRS-shGFP non-targeting vector, or shRNA targeting H-Ras were lysed 
and samples analyzed by SDS-PAGE and Western blotting with antibodies against the proteins 
indicated. (b) TaqMan gene expression analysis was performed to detect Bcl-2 mRNA in H-510 
cells stably transfected with pRS-shGFP non-effective vector, or shRNA targeting H-Ras.          
*, p<0.05. (c) H-510 cells stably transfected with pRS-shGFP non-effective vector or shRNA 
targeting H-Ras were incubated with increasing concentrations of RAD001. Cell proliferation 
was assessed using the MTS assay after 3 days. The data are mean with SD from 3 
independent experiments performed in quadruplicates. *, p<0.05. 
 
Fig. 5 Bcl-2 protein expression modulates the sensitivity of SCLC cells to RAD001. (a and 
b) Equal amounts of lysates from purified human Type II lung epithelial cells (N), or human 
SCLC cell lines (as indicated) were analyzed by SDS-PAGE and Western blotting with 
antibodies specific for the proteins indicated. The Western blots were quantified by densitometry 
(b). (c) H-510 cells were transiently transfected with Bcl-2 anti-sense (AS) or scrambled control 
(Sc). Cell lysates were analyzed by SDS-PAGE and Western blotting with antibodies specific for 
Bcl-2. (d) Cell proliferation of H-510 cells transiently transfected with Bcl-2 antisense (open 
squares) or scrambled control (closed squares) was assessed using the MTS assay after 3 
days. The data are mean from 3 independent experiments performed in quadruplicates. *, 
p<0.05. (e) H-510 cells were incubated with increasing concentrations of RAD001 in the 
presence or absence of 40μM EM20-25. Cell proliferation was assessed using the MTS assay 
after 3 days. The data are mean from 3 independent experiments performed in quadruplicates. 
*, p<0.05, **, p<0.001. (f) H-510 cells were incubated with increasing concentrations of RAD001 
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in the presence or absence of 40μM EM20-25. Caspase 3/7 activation was assessed using the 
Caspase-Glo 3/7 Assay after 3 days. The data are mean from 3 independent experiments 
performed in quadruplicates. *, p<0.05.  
 
 
Fig. 6 A siRNA targeting mTOR selectively impairs cell proliferation in H-69, but not H-510 
SCLC cells. (a-b) H-69 or H-510 SCLC cells were transiently transfected with siRNA duplexes 
targeting mTOR, or with non targeting siRNA. Total cell lysates were analysed by (a) SDS-
PAGE and Western blot analysis for mTOR, Thr37/46-phosphorylated-4E-BP1 and β-tubulin as 
a loading control and (b) RT-PCR analysis was performed to detect mTOR and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH). (c) H-69 or H-510 cells were transiently transfected with 
siRNA duplexes targeting mTOR, or with non targeting siRNA. Cell proliferation was assessed 
using the MTS assay after 3 days. The data are mean from 2 independent experiments 
performed in quadruplicates. *, p<0.05. 
 
 






